Cabot Corporation 10-Q Summary: Quarter Ended March 31, 2003
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for Cabot Corporation for the three and six months ended March 31, 2003. Cabot is a global manufacturer of chemical, tantalum, and specialty fluids products. The company operates through three primary segments: Chemical Businesses (carbon black, fumed metal oxides, inkjet colorants, aerogels), Specialty Supermetals (tantalum products), and Specialty Fluids (drilling fluids). As of April 30, 2003, the company had 61,727,000 shares of Common Stock outstanding.
Key Financial Metrics
| Metric (in millions) | Q2 2003 (3 Months) | Q2 2002 (3 Months) | YTD 2003 (6 Months) | YTD 2002 (6 Months) |
|---|---|---|---|---|
| Net Sales | $466 | $350 | $876 | $727 |
| Gross Profit | $127 | $103 | $244 | $220 |
| Income from Operations | $57 | $38 | $110 | $96 |
| Net Income | $23 | $26 | $57 | $64 |
| Income Available to Common Shares | $22 | $25 | $55 | $62 |
| Diluted EPS | $0.33 | $0.36 | $0.81 | $0.90 |
| Cash from Operating Activities (YTD) | $56 (2003) vs $45 (2002) | |||
| Cash and Equivalents (End of Period) | $131 | |||
| Total Debt (Long-term + Current) | $548 ($536 LT + $12 Current) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 33% year-over-year for the quarter ($466M vs $350M) and 21% year-over-year for the six-month period ($876M vs $727M). Growth was driven by volume increases in the Chemical and Supermetals segments.
- Profitability Decline: Despite revenue growth, Net Income decreased 12% for the quarter ($23M vs $26M) and 11% for the six-month period ($57M vs $64M). This was primarily due to a $22 million non-operating special charge in 2003 compared to $3 million in 2002.
- Segment Performance:
- Chemical Businesses: Sales up 21% (Q2), but operating profit down 23% due to rising raw material costs outpacing price increases.
- Supermetals: Sales up 123% (Q2) and operating profit up significantly due to full consolidation of Cabot Supermetals Japan and higher volumes, despite lower average selling prices.
- Specialty Fluids: Sales declined 33% (Q2) due to reduced drilling activity in the North Sea.
- Special Charges: The company recorded a $22 million impairment charge related to investments in Sons of Gwalia ($21M) and Angus and Ross ($1M), plus $1 million in corporate restructuring costs. This reduced the effective tax rate to 19% for the quarter.
Outlook, Risks, and Unusual Items
- European Restructuring: In May 2003, the Board authorized exploration of European restructuring initiatives, including the closure of a carbon black facility in Spain. This is expected to result in a pre-tax charge of approximately $60 million over 18-24 months, with roughly $30 million anticipated in the second half of fiscal 2003.
- Respirator Litigation: Cabot faces ongoing liability related to safety respiratory products acquired from American Optical Corporation. As of March 31, 2003, there were approximately 74,000 pending claimants. The company has a $6 million reserve but states it cannot reasonably estimate the range of possible loss for future claims. A global settlement is being negotiated to limit liability to a fixed annual amount.
- Antitrust Litigation: Cabot is named in multiple antitrust lawsuits alleging price-fixing in the carbon black market. The company believes it has strong defenses.
- Deferred Revenue: Approximately $10 million of revenue is deferred related to multi-year supply contracts with declining prices, to be recognized through 2006.
- Management Commentary: Management is cautiously optimistic about the Chemical segment due to lower raw material costs and volume trends. The Supermetals segment benefits from long-term contracts despite weak global electronics markets.
Investor Verification Checklist
- Investment Impairment: Verify the valuation methodology and recoverability of the remaining investments in Sons of Gwalia and Angus and Ross following the $22 million write-down.
- European Restructuring Costs: Monitor the progress of regulatory approvals and Works Council consultations regarding the $60 million restructuring charge and potential impact on future cash flows.
- Respirator Liability Exposure: Track the status of the global settlement negotiations with the "Payor Group" and the number of new claims filed, particularly in Mississippi, to assess the adequacy of the $6 million reserve.
- Carbon Black Margins: Assess the company's ability to pass on raw material cost increases to customers in the Chemical segment to restore operating margins.
- Debt Covenants: Confirm continued compliance with financial covenants on the $78 million yen term loan and the $162 million Euro loan, especially given the upcoming restructuring charges.